Immunosuppressive activities of deoxyspergualin. II. The effect on the antibody responses. 1987

M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
Laboratory of Immunology, Niigata University School of Medicine, Japan.

We examined the suppressive effect of a newly developed antitumor agent, 15-deoxyspergualin (DSP), on the plaque-forming cell responses to various antigens. The intraperitoneal injections of DSP at a dose of 5.0 mg/kg body weight suppressed drastically the development of plaque-forming cells in the spleen of C57BL/6 mice immunized with sheep red blood cells (0.2 ml of a 5% suspension), trinitrophenyl-lipopolysaccharide (1 microgram/mice) and trinitrophenyl-Ficoll (100 micrograms/mice). These suppressive effects were observed when the administration of DSP was started after the injection of antigens. The responsiveness of spleen cells from DSP-treated mice was also checked in in vitro culture. Responsiveness to lipopolysaccharide in vitro was not reduced. Furthermore DSP did not significantly suppress the responsiveness of spleen cells to succinylated concanavalin A or production of interleukin-1 or -2. The results are discussed with regards to the mode of action of DSP on immune responsiveness.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
April 1987, The Journal of antibiotics,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
February 1991, Transplantation proceedings,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
November 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
February 1989, Transplantation proceedings,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
December 1977, Cellular immunology,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
February 1991, Transplantation proceedings,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
August 1990, Transplantation proceedings,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
November 1987, The Journal of antibiotics,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
January 1969, Allergie und Asthma,
M Makino, and M Fujiwara, and H Watanabe, and T Aoyagi, and H Umezawa
March 1995, Experimental neurology,
Copied contents to your clipboard!